Business
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif., May 06, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.
About this update from Innoviva, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/e0354830d0aae8da275850a475b43739"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dKoqQIEMu.0KSISjQGnSWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/e0354830d0aae8da275850a475b43739","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dUFzsFus8gyrXb9IdbtR6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/e0354830d0aae8da275850a475b43739","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Generated $58.6 million in revenue from resilient royalties portfolio","length":69,"tagName":"p","attribs":{}},{"type":"text","content":"Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth","length":114,"tagName":"p","attribs":{}},{"type":"text","content":"Significant value created across strategic healthcare asset portfolio","length":69,"tagName":"p","attribs":{}},{"type":"text","content":"BURLINGAME, Calif., May 06, 2026--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.","length":520,"tagName":"p"},{"type":"text","content":""We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful value creation across our strategic healthcare assets," said Pavel Raifeld, Chief Executive Officer of Innoviva. "IST achieved 37% year-over-year net product sales growth in the first quarter of 2026, including 29% growth in U.S. sales."","length":409,"tagName":"p"},{"type":"text","content":""We also remained active in executing our capital allocation priorities, including increased activity under our $125 million share repurchase p...